Endothelial ERK signaling controls lymphatic fate specification

Area of Science:

• Developmental Biology
• Molecular Biology
• Genetics

Background:

• Lymphatic vessel formation is crucial for development and fluid homeostasis.
• The precise molecular triggers for lymphatic endothelial cell (EC) differentiation remain incompletely understood.
• Noonan syndrome and related RASopathies exhibit lymphatic abnormalities, suggesting a genetic basis.

Purpose of the Study:

• To investigate the molecular mechanisms underlying lymphatic vessel development.
• To determine the role of RAF1 signaling in lymphatic EC fate specification.
• To elucidate the link between RAF1 mutations, ERK activation, and lymphatic abnormalities in Noonan syndrome.

Main Methods:

• Generated transgenic mice with endothelial-specific, inducible expression of a gain-of-function RAF1(S259A) mutation.
• Analyzed gene expression changes (SOX18, PROX1) and signaling pathway activation (ERK) in endothelial cells.
• Assessed lymphatic vessel development and morphology, including lymphangiectasia.
• Utilized ERK signaling inhibitors to evaluate rescue of lymphatic phenotypes.

Main Results:

• Endothelial expression of mutant RAF1(S259A) activated ERK signaling.
• Activated ERK led to increased SOX18 and PROX1 expression, promoting lymphatic EC differentiation.
• Excessive lymphatic EC production resulted in lymphangiectasia, mimicking Noonan syndrome phenotypes.
• Inhibition of ERK signaling during development prevented lymphatic abnormalities.

Conclusions:

• ERK activation is a key regulator of lymphatic EC fate specification.
• Gain-of-function RAF1 mutations, through ERK activation, cause lymphatic abnormalities seen in Noonan syndrome and RASopathies.
• Targeting ERK signaling may offer therapeutic potential for lymphatic disorders.